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Abstract: Adipose-derived stromal/stem cells (ASCs) are currently being considered for clinical use
for a number of indications. In order to develop standardized clinical protocols, it is paramount to
have a full characterization of the stem cell preparations. The surface marker expression of ASCs has
previously been characterized in multiple studies. However, most of these studies have provided
a cross-sectional description of ASCs in either earlier or later passages. In this study, we evaluate
the dynamic changes of 15 different surface molecules during culture. Using multichromatic flow
cytometry, ASCs from three different donors each in passages 1, 2, 4, 6, and 8 were analyzed for
their co-expression of markers associated with mesenchymal stem cells, wound healing, immune
regulation, ASC markers, and differentiation capacity, respectively. We confirmed that at an early
stage, ASC displayed a high heterogeneity with a plethora of subpopulations, which by culturing
became more homogeneous. After a few passages, virtually all ASCs expressed CD29, CD166 and
CD201, in addition to canonical markers CD73, CD90, and CD105. However, even at passage 8,
there were several predominant lineages that differed with respect to the expression of CD34, CD200
and CD271. Although the significance of remaining subpopulations still needs to be elucidated, our
results underscore the necessity to fully characterize ASCs prior to clinical use.
Keywords: adipose-derived stem cells; immunophenotype; co-expression; subpopulations;
regenerative medicine
1. Introduction
Adipose-derived stromal/stem cells (ASCs) are a favorable type of mesenchymal stem cell (MSC)
due to easy accessibility, high cell yield, and robust proliferative capacity [1,2]. ASCs have been
recognized to be highly biologically active, with regenerative roles in tissue formation, homeostasis,
and immune regulation [3–5]. These unique properties render ASCs attractive in scenarios where
the traditional approaches fall short of the desired therapeutic outcome, such as for chronic wounds,
diabetic ulcers, osteoarthritis, ischemic heart disease, or type 1 diabetes, just to mention a few important
areas [6–10]. Many ASC-based regimens have already progressed into clinical testing, and in the United
States alone, more than 20 phase I and II clinical trials are currently being conducted (clinicaltrials.gov).
All of the protocols are based on the use of crude ASC cultures, which are heterogeneous mixtures
containing various stem and progenitor cells that differ functionally and immunophenotypically.
Additionally, the properties and ratios of these subpopulations have been shown to change along with
in vitro expansion [11]. It is unlikely that all lineages within the cell preparation participate to the
same extent in the therapeutic effect [12]. Provided that the discrete subpopulations can be linked
with particular functionalities, it would be possible in the prospective cell-based protocols to tailor the
desired properties to the clinical application, which would undoubtedly benefit the clinical outcome.
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Int. J. Mol. Sci. 2020, 21, 1408 2 of 16
The analysis of surface epitope expression is a powerful tool to identify and isolate stem cells.
Initially, in addition to plastic adherence and capacity for tri-lineage differentiation, a very specific
triad of cluster of differentiation (CD) molecules CD73, CD90, and CD105 was claimed to represent the
quintessential ASC hallmark [13]. However, the ensuing research lacks consensus in regard to the full
stem cell marker profile of ASCs [1,14–16]. Additionally, many other molecules have been reported in
association with ASCs, but their expression still remains controversial and is believed to be affected by
donor-to-donor variability, differing protocols of isolation and expansion, and diverse experimental
techniques [17–22]. In addition to investigations aiming at the descriptive characterization of the
surface marker expression, a great effort was dedicated to elucidating the relationship between the
phenotypical features and the functional properties. Indeed, some phenotypes displaying specific
patterns of positivity and negativity for a limited number of selected markers have been found to
possess an enhanced functionality, such as increased differentiation potential, pro-angiogenic effect,
and higher proliferative rate or modulation of the immune response [15,23–29].
In our previous work, while looking at six CD markers, we demonstrated that only 8% of all
possible combinations were present [12]. Thus, it is plausible that the heterogeneity of ASC cultures is
limited with only a restricted number of variants, depending on the permissive combinations of the CD
markers. To shed more light on the possible combinatorial repertoires, we, in the current study, based
on a thorough literature search, highly expanded the number of membrane molecules to 15 markers and
examined their triple co-expression according to functional grouping into 5 categories, including MSC
markers, wound healing, immune regulation, ASC markers, and differentiation capacity [24,25,27–45].
This was done in the search for better insight into the dynamic changes of the immunophenotypical
subsets and to elucidate the significance of the choice of donor and the effect of culture expansion. We
found that at an early stage, ASCs displayed a high heterogeneity with a plethora of subpopulations,
which by culturing became homogenized due to three ways of re-distribution: exchange, converge, or
diverge. This was independent of the choice of donor; however, donor-dependent differences in the
dynamic of some ASC subsets were discovered.
2. Results
2.1. Temporal Changes of ASC Surface Markers during In Vitro Expansion
Stromal vascular fractions (SVF) from the three donors were seeded and expanded at standard
cell culture conditions for 8 passages (P) with an average of 1.76 population doublings per passage.
The cultures underwent the most dramatic morphological changes during the first expansion, where
the cells evolved from pleiomorphic appearance to more uniform, fibroblast-resembling types in the
early P1 (Figure 1).
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Figure 1. Development of adipose-derived stromal/stem cell (ASC) morphology after isolation (P0),
and establishment of passage 1 (P1). Original magnification 200×. Scale bar indicates 100 µm.
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To study the immunophenotypical changes of ASCs during the expansion period, 15 markers,
including CD73, CD90, CD105, CD248, CD200, CD201, CD36, CD274, CD29, CD166, CD34, CD146,
CD31, CD27, and the Stro-1, were selected based on their relevance for ASCs and their proposed
functionality. For the analysis, the markers were sorted by function into five panels: MSC markers,
wound healing, immune regulation, ASC markers, and differentiation capacity (Table 1). Each panel
thus consisted of three markers, which were then assayed simultaneously using multi-color flow
cytometry. This setup enabled the follow-up of expressional kinetics of individual markers as well as
the evolution of more complex co-expressional patterns.
Table 1. Panel design for flow cytometry.
Panels Cytometer Setup
Fluorochrome1. MSC
Markers
2. Wound
Healing
3.
Immune
Regulation
4. ASC
Marker
5.
Differentiation
Capacity
Laser EmissionChannel
CD201
405 nm
450/45BP BV421
CD105 525/40BP BV510
CD166 CD36 610/20BP BV605
CD29 660/20BP BV650
CD146
561 nm
610/20BP PE-CF594
FVS570 FVS570 FVS570 FVS570 FVS570 585/42BP Viability dye
CD271 CD200 CD34 780/60BP PE-Cy7
CD248 Stro-1
638 nm
660/20BP AF647
CD274 712/25BP APC-R700
CD31 780/60BP APC-Cy7
CD73
488 nm
525/40BP FITC
CD90 690/50BP PerCP-Cy5.5
ASC; adipose-derived stromal/stem cells, MSC; mesenchymal stem cell„ BP; band pass, FVS570; fixable viability
stain 570, AF647; Alexa Fluor 647.
When looking at the expression of single markers, only the integrin β-1 (CD29; Panel 3) was
consistently expressed, irrespective of the culture period (Figure 2). Not surprisingly, the MSC
prototypical markers from Panel 1 stabilized with culture time, but the CD166 and CD201 from Panels 2
and 5, respectively, also followed this pattern. The ASC markers in Panel 4 generally diminished during
the culture, whereas the markers associated with wound healing (Panel 2), immune regulation (Panel 3),
and differentiation (Panel 5) remained expressed at variable levels throughout the culture period.
Int. J. Mol. Sci. 2020, 21, 1408 4 of 16
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2.2. Evolution of Co-Expression Patterns
The prevalence of complex immunophenotypes within the functional panels and their temporal
changes over eight passages are presented in Figure 4. Overall, only a limited number of variants out of
all possible marker combinations was identified, and two distinct evolutionary patterns were discernible.
In the majority of cases (Panels 1, 2, and 4), the spectrum of examined triple combinations was rather
broad early in the culture (P1) but became rapidly reduced at the following passage or P4 at the latest.
Interestingly, these changes are also coincident with the increase in the uniformity of cell cultures, as
described in the previous section. The selected combinations then continued being stably expressed
for the remainder of the culture. In the other pattern, there were few dominant immunophenotypical
variants that remained present throughout the whole culture period. The quantitative relationships
between early and late passages are presented in more detail in Figure S1. Furthermore, it should
Int. J. Mol. Sci. 2020, 21, 1408 6 of 16
be noted that the evolution of some particular phenotypes was clearly donor-dependent. Donor 1
exhibited particularly significant discrepancies, mostly in Panel 2, but also in Panels 4 and 5 (Figure S2).
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In order to obtain a better understanding of the evolutionary processes in the cultures, we looked
into what shifts in the marker expression occurred as a result of continued culturing (Figure 5).
Regarding Panel 1, a convergence from single- or double-expressed markers to a triple co-expression
took place. In Panel 2, the phenotypes switched through the acquisition of single CD166, and in Panel 4,
a divergence occurred where the CD146+CD34+ phenotype shed only the CD146 or both the CD146
and CD34.
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with different functionalities, a d with a transcriptional pattern wh ch evolves along with the expansion
of t e population [39,46]. Moreover, donor variation and fat tissue origin are addi ional contributing
factors that have a major influence on t e prevalence of particular immunophenotypes [18,36,47]. It
can be s ecula ed that these factors may be the source of variation between studie and the re son for
suboptimal outcomes of some pre-clinical and clinical trial [36,48–52] and that it is plausible that by
establishing a reliable association betwe n some predictive biomarkers, such as surface membran
im unophenotype and clinical efficacy, ASC potential could be exploited to its fullest in the future. To
dat , the evolu ion of complex co-expressed immunophenotypic repertoires within ASC cultu has
not been expl red in a systematic fashion. Th s, as a fir t step, we have in the current study invoked
15 well-defined urface pitopes and followed their temporal changes in triple co-express on pattern
using fat samples from five independent donors.
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Not surprisingly, our investigation of single-marker expression corroborated well-established
evidence regarding the uniform expression of hallmark antigens CD73, CD90, CD105, CD166, and
CD29, and absence of CD31 in stages following P0 [17,18,46,53–56]. Nevertheless, some substantial
discrepancies in previous data were uncovered with several markers as well. For instance, while the
CD34 has initially been claimed not expressed [13] and some authors later were able to detect it in the
early stages after primary isolation [46,57], our experiments revealed a robust expression between 30%
and 90% (Figure 2). By the same token, in the light of previous reports indicating lack of expression
of Stro-1 [20] which in retrospect may be attributed to antibody sources and detection methods [58],
we could consistently identify this marker—albeit at a wide span of levels—ranging from around
3% to more than 50%, supporting the findings of Ning et al. and Zuk et al. [59,60]. This may be of
biological importance due to Stro-1 being involved in clonogenicity, homing, and angiogenesis [7].
Less dramatic, though still considerable differences in expression levels were noticed for other surface
markers, including CD36, CD146, CD200, CD201, and CD271 [18,34,61–63]. When using quantitative
immunofluorescence techniques, such as multicolour flow cytometry, it is difficult to achieve absolute
accuracy, unless highly prevalent and expressed epitopes are searched for. Additionally, results may
vary depending on experimental set-up and instrumentation; proper cross-bleed compensation is
also critical. Inconsistencies among data from independent laboratories, which can, for the most
part, be attributed to donor- and/or tissue-source-related idiosyncrasies, can further be burdened by
these experimental artefacts. It is therefore imperative that the subjects and procedures involved in
tissue processing and marker analysis be adequately described and standardized as much as possible.
Having previously been faced with the pitfalls of the multichromatic fluorescence cell sorting [12], it
is our assumption that the discrepancies reported herewith are mostly attributable to the biological
nature of our samples.
Despite the fact that our study enabled direct exploration of only triple marker combinations,
based on the temporal patterns of individual markers as highlighted above, it is possible
to infer that after the initial few passages, all cells came to express the common phenotype
CD73+CD90+CD105+CD166+CD29+CD201+. The CD73+CD90+CD105+ triple positivity denotes
stem/progenitor cells [13], and it is interesting that these cells became enriched by in vitro growth.
Similarly, it is intriguing that a subset of these cells exhibiting the CD31−CD34+CD146− profile,
previously found to identify a stem cell lineage [25,64,65], also grew proportionally to the culture
period. In addition, possibly important ramifications may reveal that some antigens that have been
ambiguously associated with stemness, including CD200, CD248, and CD271 [66,67], were reinforced
during the culture, while all subsets featuring CD146, which has previously been recognized as a
surrogate for stemness [40,68–71] were sequestered. Concerning interpersonal variability, the spread
of the data roughly follows previously reported trends [49,72], except for two specific subsets, the
CD166+CD271−CD248+ and CD166+CD271+CD248+, which were identified only in a single donor. It
seems reasonable to assume that similar variations underlie, at least in part, the unique properties
observed with some donors [36,52,73,74], but implications for providing a carrier with a selective
advantage through a specific biological mechanism remain to be elucidated. In the light of a clinical
advantage, researchers are beginning to look into the biological mechanism of specific co-expressed
surface marker profiles [75–77]. It was found that CD34/CD90 double-positive cells was present after
30-days of expansion and that they may play a vital role in tissue reconstruction. Additionally, we
have earlier found the subpopulation CD73+CD90+CD105+CD34-CD146+CD271− to have a positive
effect on endothelial cells [12]. Consequently, it is worth continuing investigations of the biological
effects of these interesting subsets to gain a more comprehensive understanding of the mechanism of
action of ASCs.
Based on our data, it is obvious that even after a major homogenization of the immunophenotypical
repertoire taking place at P1, stabilized discrete lineages remain within the culture population that can
be discriminated, at least in our case, by the expression of CD34, CD200, CD248, and CD271. It appears
worthwhile that the highly defined subpopulations within ASC cultures are to be studied using at least
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a set of markers as outlined in this study, since such an investigation might reveal hitherto unknown
relationships between the immunophenotypical profiles and functionality. This kind of information
may be greatly beneficial for improving the efficacy of future ASC therapeutic applications.
4. Materials and Methods
4.1. ASC Isolation and Expansion
Adipose tissue samples used in this study were derived from five healthy donors who underwent
cosmetic liposuction surgery at Aarhus University Hospital, Aarhus, Denmark or Aleris-Hamlet
Private Hospital, Aalborg, Denmark. Written informed consent was obtained from each donor prior
to donation, and our study was approved by the regional committee on biomedical research ethics
on Northern Jutland (Project No. N-20160025, 17 April 2016). Tissue was collected according to
Danish legislation on anonymized tissue (Komitélov §14), and the collection complied with the
principles defined by the Declaration of Helsinki. ASCs were isolated as described previously in our
laboratory [78]. In brief, after being washed four times with sterile phosphate-buffered saline (PBS;
Gibco, Taastrup, Denmark), adipose tissue was digested with 0.6 U/mL collagenase NB 4 standard
grade (Nordmark Biochemicals, Uetersen, Germany) in Hanks’ Balanced Salt Solution (Gibco, Taastrup,
Denmark) for 1 h at 37 ◦C under continuous agitation. The obtained dissociated tissue was filtered
through a 100 µm filter (Millipore, Omaha, NE, USA) followed by low-speed centrifugation at 400× g
for 10 min. After removing the supernatant, the cell pellet was resuspended in growth media that was
alpha-Minimum Essential Medium with GlutaMAX supplemented with 10% fetal calf serum (FCS) and
1% antibiotics (all from Gibco, Taastrup, Denmark), filtered through a 60 µm filter (Millipore Omaha,
NE, USA), and, finally, centrifuged at 400 g for 10 min.
The acquired cell pellet was resuspended in the growth medium, and cell yield was determined by
the Nucleocounter NC-200 cell counter (Chemometec, Allerod, Denmark). Consequently, the resulting
cells were seeded into T175 culture flasks (Greiner Bio-one, Frickenhausen, Germany), and these initial
cultures were referred to as passage 0 (P0). At 70%–80% confluency, the cells were detached using
TryPLE (Gibco, Taastrup, Denmark), and all the following cultures (P1–P8) were initiated at a density
of 5000 cells/cm2 [30]. During culture, the medium was changed every 2–3 days.
4.2. Multichromatic Flow Cytometry
Initially, ASCs from three donors were analyzed at P1, 2, 4, 6, and 8 in regard to 15 selected surface
epitopes. To further examine the range of inter-donor variability, two additional donors were included
in passages P1, 4, and 8. The 15 directly-labeled antibodies used to detect the surface epitopes were
assorted in five panels of triple combinations based on functionality (Table 1) and used simultaneously
with Fixable Viability Stain 570 (FVS570) (BD Biosciences, Lyngby, Denmark) to exclude the dead cells
from analysis. For technical details about antibodies, see Table A1. For staining, cell suspensions
were first filtered through a cell strainer (70 µm; BD Falcon; BD Bioscience, Erembodegem, Belgium)
and subsequently dispensed at 2 × 105 cells per reaction tube. Cells were initially incubated with the
viability reagent for 15 min at room temperature, after which a mixture of antibodies optimally diluted
in PBS supplemented with 2% FCS and 0.1% sodium azide (Merck Schuchardt, Hohenbrunn, Germany)
was added. In Panel 5, where two or more BD Horizon Brilliant dyes were used, BD Horizon Brilliant
Stain Buffer (BD Bioscience, Erembodegem, Belgium) was used as a diluent. After staining for 30 min
at 4 °C in the dark, the samples were washed twice with 50% Accumax (Sigma-Aldrich, Copenhagen,
Denmark) in PBS to prevent cell aggregation. For each panel at each passage, two or three independent
staining experiments were conducted.
For surface epitope analysis, a CytoFLEX (Beckman coulter, Copenhagen, Denmark) flow cytometer
was employed. Prior to analyzing the samples, compensation values were established with the aid
of the BD CompBeads Plus Set Anti-mouse Ig, κ and Anti-rat Ig, κ (BD Biosciences, Erembodegem,
Belgium) and invoking a compensation matrix based on the dot-plots delineating the combination of
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channels used in the particular experiment. The data were visualized and analyzed in the Kaluza 2.1
software package (Beckman Coulter, Indianapolis, IN, USA). To validate data analysis, four gates were
adopted: one to remove debris (forward scatter area vs. side scatter area); one to ensure cell flow and
flow cytometer stability (forward scatter area vs. time); one to discriminate doublets (forward scatter
area versus forward scatter height); and one to eliminate dead cell (viability dye intensity histogram).
Fluorescence minus one (FMO) controls were used to define the cutoff limit for background values,
which was generically set at 97.5th percentile. The gating strategy can be seen in Figure A1.
4.3. Statistical Analysis
The data entailing 2–3 replicates for each passage derived from each of the three donors were
presented as mean + standard deviation (SD). The General Linear Model (GLM) procedure with
repeated measures followed by post-hoc tests of the IBM SPSS Statistics v.26 software package (IBM,
Armonk, NY, USA) was utilized to assess the differences between the passages and donors. The level
of significance was set at 0.05.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/4/1408/
s1.
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ASC Adipose-derived stromal/stem cells
BP Band pass
CD Cluster of differentiation
FCS Fetal calf serum
FMO Fluorescence minus one
FSC-A Forward scatter area
FSC-H Forward scatter hight
FVS570 Fixable viability stain 570
GLM General linear model
MSC Mesenchymal stem cells
P Passage
SD Standard deviation
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Table A1. Technical details on antibodies and reagents used for flow cytometry.
Fluorophore Antigen Host Company Catalog Number
BV421 CD201 rat BD Biosciences 743552
BV510 CD105 mouse BD Biosciences 563264
BV605 CD166 mouse BD Biosciences 742373
APC-R700 CD274 mouse BD Biosciences 565188
APC-Cy7 CD31 mouse BD Biosciences 563653
FITC CD73 mouse BD Biosciences 561254
BV605 CD36 mouse BD Biosciences 563518
BV650 CD29 mouse BD Biosciences 743785
PE-Cy 7 CD200 mouse BD Biosciences 562125
PE-Cy7 CD271 mouse BD Biosciences 562122
Alexa Fluor 647 CD248 mouse BD Biosciences 564994
Alexa Fluor 647 Stro-1 mouse R & D system FAB1038R
Percp-Cy5.5 CD90 mouse BD Biosciences 561557
PE-CF594 CD146 mouse BD Biosciences 564327
PE-Cy7 CD34 mouse BD Biosciences 560710
Product Name Company Catalog Number
BD Horizon™ Brilliant Stain Buffer BD Biosciences 563794
Viability dye, FVS570 BD Biosciences 564995
CompBeads Plus Set Anti-mouse Ig, κ BD Biosciences 560497
CompBeads Plus Set Anti-rat Ig, κ BD Biosciences 560499
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Figure A1. Gating strategy for flow cytometry. (A) Noise was removed to collect the cell population 
using forward scatter area (FSC-A) versus side scatter area (SSC-A). (B) To ensure a stable flow during 
data aquisition, the FSC-A versus time plot was controlled. (C) To exclude dead cells, viability dye 
(FVS570) was used. (D) The doublets were discriminated via FSC-A versus forward scatter height 
(FSC-H). (E) Representative of the overlay histogram of the unstained, fluorescence minus one (FMO) 
and stained group. Red box: the threshold was set at the 2.5% of FMO. 
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